Xu Xunjia, Yin Shi, Liu Huijuan, Zhao Ruixia, Cui Weifeng, Shao Mingyi, Yu Haibin, Yan Shuxun, Fu Yu
Department of Endocrinology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, 450000, People's Republic of China.
The First School of Clinical Medicine, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, People's Republic of China.
Diabetes Metab Syndr Obes. 2025 Aug 31;18:3135-3148. doi: 10.2147/DMSO.S541164. eCollection 2025.
Chinese herbal medicines (CHMs) are used for type 2 diabetes mellitus combined with stable angina pectoris (T2DM-SAP), but their long-term effects lack real-world evidence.
To evaluate the effects of additional CHMs on angina readmission rates compared to standard treatment alone in patients with T2DM-SAP.
This retrospective cohort study included 704 patients with T2DM-SAP. Participants were stratified into two groups based on cumulative CHMs use (≥ 3 months). The CHMs group included 115 patients, while the non-CHMs group included 589 patients. A 1:1 propensity score matching (PSM) was used to balance differences between groups. The primary outcome was angina readmission. The secondary outcomes were SAP readmission and unstable angina pectoris (UA) readmission. Kaplan-Meier survival curves were plotted before and after matching. Sensitivity analysis was performed using Cox proportional hazards model. Baseline prescriptions were collected and herbal frequency and efficacy were counted.
After matching, there were 106 patients in each of the two groups. Before matching, compared with the non-CHMs group, the adjusted hazard ratio (aHR) of angina readmission in the CHMs group was 0.49 [95% confidence interval (CI): 0.34, 0.71, <0.001]. After matching, the aHR was 0.37 [95% CI: 0.22, 0.60, <0.001]. The reliability of the results was confirmed by sensitivity analyses adjusted for different covariates. The CHMs group demonstrated a significantly longer median time to angina readmission compared to the non-CHMs group (55.66 vs 13.90 months, <0.001). Similar results were also shown after matching. 115 prescriptions involving 220 herbs were collected.
Additional CHMs treatment can significantly reduce the incidence of angina readmission and prolongs the interval to recurrent events in T2DM-SAP patients.
中药用于2型糖尿病合并稳定型心绞痛(T2DM-SAP),但其长期疗效缺乏真实世界证据。
评估与单纯标准治疗相比,加用中药对T2DM-SAP患者心绞痛再入院率的影响。
这项回顾性队列研究纳入了704例T2DM-SAP患者。参与者根据累计使用中药情况(≥3个月)分为两组。中药组包括115例患者,非中药组包括589例患者。采用1:1倾向评分匹配(PSM)来平衡组间差异。主要结局是心绞痛再入院。次要结局是SAP再入院和不稳定型心绞痛(UA)再入院。匹配前后绘制Kaplan-Meier生存曲线。使用Cox比例风险模型进行敏感性分析。收集基线处方并统计中药使用频率和疗效。
匹配后,两组各有106例患者。匹配前,与非中药组相比,中药组心绞痛再入院的调整后风险比(aHR)为0.49 [95%置信区间(CI):0.34, 0.71, <0.001]。匹配后,aHR为0.37 [95% CI:0.22, 0.60, <0.001]。通过针对不同协变量调整的敏感性分析证实了结果的可靠性。与非中药组相比,中药组心绞痛再入院的中位时间显著更长(55.66对13.90个月,<0.001)。匹配后也显示了类似结果。收集了涉及220种草药的115份处方。
加用中药治疗可显著降低T2DM-SAP患者心绞痛再入院的发生率,并延长复发事件的间隔时间。